search
PIPAC is a new method to deliver intr-aabdominal chemotherapy. Recent studies focused on patients with unresectable peritoneal metastases from gastric cancer have shown median overall survivals of 14-20 months, suggesting that this therapy might offer survival benefits to these patients with very bad prognosis. However, in 2021, PIPAC is still considered only as a palliative treatment, and the rest of indications should be performed only within clinical trials. Following the ideas of the pioneer of the technique, Prof. Rerymond, this video will focus the current evidence and future trials of this therapy for patients with gastric peritoneal carcinomatosis.